Table 2: Comparison of demographic features, clinical characteristics and treatment between SLE patients with graft failure and functioning graft.

Graft failure ( )Functioning graft ( )

Gender female (%)14 (93%)27 (77%)0.169
Age at diagnosis SLE (years)22.4 ± 1022.8 ± 110.758
Age at renal Tx (years) 41.3 ± 10.238.7 ± 12.00.280
Time SLE-nephritis (months)17 ± 42.634.9 ± 750.412
Time nephritis dialysis (months)39 ± 45.588.7 ± 80.60.038
Time on dialysis (months)73.9 ± 60.635.7 ± 35.40.011
Time nephritis-Tx (months)114.6 ± 64.2 120 ± 73.30.880
Dialysis before renal Tx (%):
 HD14 (93.3%)19 (76.0%)0.168
 CAPD2 (13.3%)7 (28.0%)0.251
 HD and CAPD1 (6.7%)
3 (12.0%)0.516
Tx date (years)1998 ± 72004 ± 60.036
Donor source (%):
 Cadaveric13 (86.7%) 16 (45.7%)0.007
 Living donor2 (13.3%)19 (54.3%)
Immunosuppressive regimen at Tx (grafts) (%):
 Cyclosporine A10 (66.6%)9 (25.7%)0.006
 Mycophenolic acid8 (53%)31 (88.6%)0.003
 Tacrolimus4 (27%)23 (66%)0.012
Positive anti-HCV antibodies (patients) (%)12 (80%)10 (28.6%)0.001
Positive aPL antibodies (%)1 (6.7%)11 (31.4%)0.058

Quantitative variables are presented as mean ± standard deviation and qualitative variables as number (percentage).
SLE: systemic lupus erythematosus; Tx: transplantation; HD: hemodialysis; CAPD: continuous ambulatory peritoneal dialysis; HCV: hepatitis C virus; aPL: anti-phospholipid antibodies.